Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheli Melzer Cohen

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|June 29, 2023
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney DiseaseCheli Melzer Cohen, Meir Schechter, Aliza Rozenberg, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 22, 2020
Very Low Birth Weight Preterm Infants have Decreased Celiac Disease Autoimmunity During Childhood and AdolescenceAmir Ben Tov, Shlomi Cohen, Raanan Shamir, et al.
Cardiovascular Diabetology|June 10, 2022
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adultsMeir Schechter, Cheli Melzer Cohen, Ilan Yanuv, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 studyCarolyn S P Lam, Avraham Karasik, Cheli Melzer-Cohen, et al.
Cardiovascular Diabetology|May 27, 2023
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidenceMeir Schechter, Cheli Melzer Cohen, Alisa Fishkin, et al.
Journal of Diabetes and Its Complications|June 21, 2016
Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence studyInbal Goldshtein, Avraham Karasik, Cheli Melzer-Cohen, et al.
Diabetes Care|October 25, 2022
Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and IsraelBeini Lyu, Yingying Sang, Elizabeth Selvin, et al.
Diabetologia|June 6, 2022
Obesity in late adolescence and incident type 1 diabetes in young adulthoodInbar Zucker, Yair Zloof, Aya Bardugo, et al.
The Lancet. Diabetes & Endocrinology|December 22, 2019
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort studyHiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, et al.
Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Clinical Journal of the American Society of Nephrology : CJASN|June 29, 2023
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney DiseaseCheli Melzer Cohen, Meir Schechter, Aliza Rozenberg, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 22, 2020
Very Low Birth Weight Preterm Infants have Decreased Celiac Disease Autoimmunity During Childhood and AdolescenceAmir Ben Tov, Shlomi Cohen, Raanan Shamir, et al.
Cardiovascular Diabetology|June 10, 2022
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adultsMeir Schechter, Cheli Melzer Cohen, Ilan Yanuv, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 studyCarolyn S P Lam, Avraham Karasik, Cheli Melzer-Cohen, et al.
Cardiovascular Diabetology|May 27, 2023
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidenceMeir Schechter, Cheli Melzer Cohen, Alisa Fishkin, et al.
Journal of Diabetes and Its Complications|June 21, 2016
Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence studyInbal Goldshtein, Avraham Karasik, Cheli Melzer-Cohen, et al.
Diabetes Care|October 25, 2022
Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and IsraelBeini Lyu, Yingying Sang, Elizabeth Selvin, et al.
Diabetologia|June 6, 2022
Obesity in late adolescence and incident type 1 diabetes in young adulthoodInbar Zucker, Yair Zloof, Aya Bardugo, et al.
The Lancet. Diabetes & Endocrinology|December 22, 2019
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort studyHiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, et al.
Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Pageof 4